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Abstract
Background/Aim. Diabetic nephropathy (DN) is a clinical
syndrome characterized by persistent albuminuria, increas-
ing arterial blood pressure and progressive decline in glo-
merular filtration rate (GFR). When persistent albuminuria
is established, antihypertensive treatment becomes most
important factor in slowing the progression of diabetic glo-
merulopathy. The aim of this study was to examine if reno-
protective response to a short-term losartan therapy de-
pends on 1166 A/C gene polymorphism for its target re-
ceptor. Method. The study included 35 patients with dia-
betes mellitus type 1 and persistently high urinary albumin
excretion rate (UAE: >  30  mg/24  h), genotyped for the
1166 A/C gene polymorphism for the angiotensin II type 1
receptor (AT1R). The participants were segregated into 3
genotype groups according to combinations of A or C al-
lele: AA(16%), AC(15%) and CC(11%). The patients re-
ceived losartan 50 mg daily for 4 weeks, following 100 mg
daily for another 8 weeks. At baseline and after 12 weeks of
the treatment period UAE, blood pressure, GFR and filtra-
tion fraction (FF) were determined. Results. After 12
weeks of the treatment with losartan, albuminuria was re-
duced from baseline by 9% [95% confidence interval
(CI): 1–17,  p  =  0.039] in the AA genotype, and by 11%
(95% CI: 6–17, p = 0.0001) in the AC genotype. Losartan
treatment reduced albuminuria in the CC group by 5%
(95%CI: -13–22, p  =  0.47). Glomerular filtration rate re-
mained unchanged in all genotype groups. Filtration frac-
tion was significantly reduced from baseline by
0.018 ± 0.024 (p = 0.012) only in the AC genotype. In the
AA genotype, FF was reduced from baseline by 0.017 ±
0.03 (p = 0.052), and in the CC genotype by 0.01 ± 0.008
(p = 0.092). In the AA group, systolic blood pressure de-
clined from 136 ± 24 mmHg at baseline, to an average of
121 ± 18 mmHg at the end of the study (p = 0.001). The
AC group achived reduction from 131 ± 10 mmHg at base-
line to 115 ± 7 mmHg (p = 0.001) during the investigation
period. In the AA genotype group losartan reduced diastolic
blood pressure from 86  ±  13  mmHg at baseline to
78 ± 8 mmHg  (p  =  0.004), and in the AC genotype from
88 ± 5 mmHg at baseline to 11.7 ± 5.6 mmHg during the
investigation period (p =  0.001). In the CC genotype dia-
stolic blood pressure reduction remained nonsignificant
(p = 0.066). Conclusion. The results of our small sample
size study provide the evidence that 1166 A/C AT1R poly-
morphism could be associated with the renoprotective re-
sponse to losartan therapy.
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Apstrakt
Uvod/Cilj. Dijabetesna nefropatija (DN) je klinički sin-
drom koji karakterišu trajna albuminurija, povišeni krvni
pritisak i progresivno sniženje jačine glomerulske filtracije.
Kada se pojavi trajna albuminurija, uvođenje antihipertenzi-
vne terapije predstavlja najvažniji faktor za usporavanje
progresije dijabetesne glomerulopatije. Naša studija imala je
za cilj da ispita u kolikoj meri je renoprotektivni odgovor na
lečenje losartanom, blokatorom receptora za angiotenzin II,
uslovljen polimorfizmom gena za njegov ciljni receptor.
Metode. Ispitivanjem je bilo obuhvaćeno 35 bolesnika sa
dijabetesom tip 1 i trajno povišenom urinarnom ekskreci-
jom albumina od preko 30 mg/24 h. Ispitanici su lečeni lo-Strana 274 VOJNOSANITETSKI PREGLED Volumen 67, Broj 4
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sartanom u dozi od 50 mg dnevno tokom četiri sedmice,
nakon čega je doza povećana na 100 mg dnevno, narednih
osam sedmica. Na početku ispitivanja i nakon 12 sedmica
lečenja izmerene su vrednosti dnevne urinarne ekskrecije al-
bumina (UEA), jačine glomerulske filtracije (JGF), glome-
rulske filtracione frakcije (FF) i sistemskog krvnog pritiska.
U zavisnosti od postojanja A i C alela u okviru 1166A/C
polimorfizma gena za receptor tip 1 angiotenzina II (AT1R),
ispitanici su bili podeljeni u tri grupe (AA, AC i CC) radi ut-
vrđivanja razlike ispitivanih parametra na početku i na kraju
lečenja. Rezultati. Posle 12 sedmica lečenja, losartan je sni-
zio albuminuriju za 9% [interval poverenja (IP) 95%: 1–17,
p = 0,039] u AA homozigotnoj grupi i za 11% (IP 95%: 6–
17, p = 0,0001) u AC heterozigotnoj grupi. Redukcija albu-
minurije kod CC homozigota nije bila značajna. Jačina glo-
merulske filtracije ostala je nepromenjena u sve tri genotip-
ske grupe. Terapija losartanom dovela je do značajnog sma-
njenja FF za 0,018 ± 0,024 (p = 0,012) jedino u AC grupi,
dok se redukcija FF u AA grupi za 0,017 ± 0,03 (p = 0,052)
približila statističkoj značajnosti. Kod CC homozigota sma-
njenje FF nije bilo značajno. U grupama  AA i AC, postig-
nuto je visoko statistički značajno sniženje i sistolnog i dija-
stolnog krvnog pritiska (p < 0,01), dok sniženje arterijskog
pritiska u CC grupi nije bilo značajno (p > 0,05). Zaključak.
Individualni renoprotektivni odgovor na terapiju losarta-
nom, bar jednim delom mogao bi biti uslovljen 1166 A/C
polimorfizmom gena za AT1R.
Ključne reči:
dijabetes melitus, insulin-zavisni; dijabetesne
nefropatije; polimorfizam, genetički; angiotenzin II;
losartan.
Introduction
Diabetic nephropathy (DN) is a clinical syndrome char-
acterized by persistent albuminuria, increasing arterial blood
pressure and progressive decline in glomerular filtration rate
(GFR) 
1. When persistent albuminuria is established (over
30 mg/24  h), antihypertensive treatment becomes most im-
portant factor in slowing the progression of diabetic glo-
merulopathy. It is recommended that this therapy should be
started as early as possible, at the microalbuminuric stage,
even if the hypertension is absent 
2.
Extensive investigations have documented the key role
of the renin-angiotensin-aldosterone system (RAAS) in the
pathogenesis and pathophysiology of diabetic renal disease.
Angiotensin II (Ang II), the major effector of this system,
acts as the circulating vasoconstrictory hormone, as well as
paracrine peptide that modulates renal function. Most of its
effects are mediated via Ang II type 1 receptors, localisated
in glomerular vascular smooth muscle cells, mesangial cells
and on the luminal surface of tubular cells. This hormone
also has the fundamental role in starting and progression of
DN by its hemodynamic and non-hemodynamic effects 
3.
Angiotensin II type receptor 1 (AT1R) antagonists are a
group of antihypertensive drugs that act on the terminal cas-
cade of RAAS by selective binding to AT1R. This provides
more complete blockade of Ang II actions in systemic and
local manner, which is especially important in diabetic state
where the intrarenal RAAS activity is enhanced 
4.
Despite good glycemic control, lipid lowering agents
and antihypertensive treatment, these patients have 3-6 times
faster decline in renal function comparing to non-diabetic
patients 
5. One of the possible reasons for currently nonade-
quate renoprotective treatment and bad prognostic values, are
individual variations in response to the first-line therapy of
these patients. This variations could be genetically influ-
enced, due to the existence of polymorphisms within the
genes that encode for enzymes related with drug metabolism,
or genes for proteins of the physiological pathway on which
the drug acts 
6, 7. Because of the central role of RAAS in
pathogenesis of DN, it would be important to evaluate the
type of genetic polymorphisms binding to this system, that
could influence individual renoprotective efficacy of drug
treatment.
As we mentioned before, most of the actions of Ang II
are mediated by stimulation of AT1R, including vasocon-
striction, regulation of the vascular tone and proliferative
processes in glomerule. Moreover, genetic variations of this
specific receptor can alter AT1R-mediated reactions by al-
tering its expression or structure 
7, 8.
This human receptor gene is composed of 5 exons and 4
introns with a length of more than 50 kb. So far, various ge-
netic polymorphisms of this receptor gene have been re-
ported, but the best evaluated of all is the 1166 A/C single
nucleotide polymorphism (SNP). This SNP is an A/C trans-
version in the 3' untranslated region of the gene 
9. There is a
growing evidence to suggest that the 1166 A/C AT1R poly-
morphism is implicated in higher risk for cardiovascular
events, and the C allele became serious candidate for genetic
variations that lead to enhanced activity of systemic and/or
paracrine RAAS 
10–13. Considering previous studies, treat-
ment with AT1R antagonists could overcome some other
forms of polymorphisms 
14, 15. We, therefore, wanted to
evaluate if the renoprotective effect of losartan could be in-
fluenced by polymorphism of its target receptor gene.
Methods
Thirty-five patients, men (n = 20) and women (n = 15),
with diabetes mellitus type 1 and persistently high urinary
albumin excretion rate (UAE > 30 mg/24h) 
16 were included
in this study  . Each patient underwent a detailed history,
physical and laboratory examination, in order to evaluate in-
clusion and exclusion criteria. Before enrollment, each pa-
tient was examined for urinary albumin excretion rate. All
patients fulfilled the following inclusion criteria: diabetes
mellitus type 1 more than 5 years; of over 18 years age and
persistently high albuminuria. The patients were excluded if
they had a history of congestive heart failure, malignant hy-
pertension, valvular heart and aortic disease, renal artery ste-
nosis, creatinin clearance less than 60  mL/min and earlierVolumen 67, Broj 4 VOJNOSANITETSKI PREGLED Strana 275
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established persistent erythrocyturia and/or urinary infection.
Dietary intake of protein or salt was not restricted.
After evaluation for the inclusion criteria, the patients
underwent the measurement of renal hemodynamic parame-
ters and blood pressure. Then, the participants received two
daily oral doses of losartan: 50 mg daily in the first 4 weeks,
followed by 100 mg for another 8 weeks. After 12 weeks of
treatment, renal hemodynamics and measurement of blood
pressure and albuminuria were repeted. The subjects were
genotyped for 1166 A/C AT1R polymorphism, and subdi-
vided into three groups (AA, AC and CC) in order to estab-
lish statistically significant differences in the examined pa-
rameters, before and after the treatment period.
Urinary albumin excretion was determined as the mean
values obtained in the two separate 24  h urine collections
using an immunonephelometric assay (BN 100 Dade Be-
hring analyzer) 
16. It was measured at baseline and again af-
ter 12 weeks of the treatment.
Blood pressure was measured using mercury sphyg-
momanometar in the seated positon after resting for at least
10 minutes and was determinated as the average of three
measurements taken 5 minutes apart 
17. During the treatment,
blood pressure was measured 24 h after the last dose.
Genomic DNAs were extracted with Applied Biosys-
tems 6 100 Nucleic Acid prep Station instrument.  Concen-
tration of DNA was determinated by measuring the optical
density at 260  nm. The A1166C gene polymorphism was
analyzed by polymerase chain reaction (PCR) and subse-
quent restriction-endonuclease digestion according to de-
scription of Dzida et al 
18. Polymerase chain reaction product
was visualized by electrophoresis on 2% agarose gel stained
with 2 μL of 10 mg/mL ethidium bromide solution.
Glomerular filtration rate was measured as the renal
uptake of 99mTc-diethylenetriaminepentaacetic acid
(DTPA), 2 to 3 minutes after traces arrival in the kidney by
the method of Goates et al 
19. A total GFR was calculated
using a formula derived from regression analysis comparing
24 h creatinine clearance to percent renal uptake:
GFR  (mL/min) = % renal uptake × 9.8127  − 6.82519;
where 9.8127 is the regression coefficient and 6.8219 the y-
intercept. The results were standardized for 1.73 m
2 body sur-
face area, using the patients surface area at the start of the study.
Effective renal plasma flow (ERPF) was measured as
the uptake of 131-iodine-lebeled hippuran in the kidney, 1 to
2 minutes after the i.v. injection, with a correction for renal
depth and with background substraction 
20. Filtration fraction
(FF) was determined by dividing GFR by ERPF 
12.
All data were presented as mean ± SD except for albu-
minuria, which was given as median (interquartile range).
The one–way ANOVA test was used to analyse between-
group and within-group differences. The paired Student’s t-
test was used to test the differences between the baseline
values and those after the treatment with losartan. The values
of albuminuria were logarithmically transformed, owing to
its skewed distribution, and then tested by the Student’s t-
test. A p-value less than 0.05 was considered statistically
singificant.
Results
The average age of the 35 patients with diabetes melli-
tus type 1 and high values of albumin excretion rate was
33 ± 9 years, and the average diabetes duration was 16 ± 7
years. All patients were genotyped for 1166 A/C AT1R
polymorphism. Sixteen subjects had the AA genotype, 15
subjects had the AC genotype, while the rest four subjects
had the CC genotype in 1166 A/C AT1R polymorphism.
There were no significant differences in the clinical pa-
rameters before the treatment with losartan among three
genotype groups (p > 0.05) (Table 1).
 After 12 weeks of the treatment with losartan, the mean
values of daily urinary albumin excretion was significantly
reduced in the AA genotype and in the AC genotype group,
while the changes of albuminuria in the CC genotype group
remained nonsignificant (Table 2). Albuminuria was reduced
from the baseline by 9% [95% confidence interval (CI):1–17,
p  =  0.039] in the AA group, and by 11% (95%CI: 6–17,
p = 0.0001) in the AC group. The losartan treatment reduced
albuminuria in the CC group by 5% (95%CI: -13–22,
p = 0.47). There were no significant differences between the
Table 1
Baseline clinical characteristics of 35 type 1 diabetic patients with high values of
daily urinary albumin excretion segregated by genotype
AA (n = 15) AC (n = 16) CC (n = 4) Patients’ characteristics
ґ  ± SD ґ  ± SD ґ  ± SD
Sex (men/women) 12/3 12/4 1/3
Age (years) 32 ± 11 34 ± 8 23 ± 3
DM duration (years) 18 ± 8 14 ± 7 13 ± 2
BMI (kg/m
2) 22.8 ± 11.28 22.8 ± 2.33 22.4 ± 1.95
HbA1c (%) 9.34 ± 1.82 8.83 ± 1.22 9.88 ± 1.62
Albuminuria (mg/24h)§ 99 (43-5838) 87 (45-830) 190 (45-854)
GFR (mL/min/1.73m
2) 97 ± 19 96 ± 20 104 ± 20
FF 0.18 ± 0.04 0.17 ± 0.03 0.19 ± 0.05
Systolic BP (mmHg) 136 ± 24 131 ± 10 133 ± 19
Diastolic BP (mmHg) 86 ± 13 88 ± 5 95 ± 6
All data are expresed as means ± SD except albuminuria. DM – diabetes mellitus; BMI – body mass
index; HbA1c – hemoglobin A1c; GFR – glomerular filtration rate; FF – filtration fraction; BP – blo-
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albuminuria reduction among three different genotype
groups during the study.
Glomerular filtration rate remained unchanged in all
examined groups (p > 0.05).
After 12 weeks of the losartan treatment, FF was sig-
nificantly reduced from the baseline by 0.018  ±  0.024
(p = 0.012) only in AC genotype. In the AA genotype, FF
was reduced from baseline by 0.017 ± 0,03 (p = 0.052), and
in the CC genotype by 0.01 ± 0.008 (p = 0.092) (Table 2).
There were no significant differences between GFR anf FF
reduction in the three examined groups during the study.
The mean values of systolic blood presssure was sig-
nificantly lowered in the AA and in the AC genotype groups,
while the CC genotype group achieved nonsignificant reduc-
tion. In the AA group, systolic blood pressure declined from
136  ±  24  mmHg (mean  ±  SD) at baseline to an average of
121 ± 18 mmHg at the end of the study (p = 0.001). The AC
group achieved reduction from 131 ± 10 mmHg at baseline
to  115 ± 7 mmHg  (p  =  0.001) during the investigation pe-
riod. Similar results were obtained in the diastolic blood
pressure reduction. In the AA genotype losartan reduced dia-
stolic blood pressure from 86  ±  13mmHg at baseline to
78 ± 8  mmHg  (p  =  0.004) during the investigation period,
and in the AC genotype from 88  ±  5mmHg at baseline to
11.7  ±  5.6  mmHg during the study (p  =  0.001). In the CC
genotype, diastolic blood pressure reduction remained non-
significant (p = 0.066) (Table 2).
There were no significant differences between systolic
or diastolic blood pressure reduction among three different
genotype groups during the study.
Discussion
The intrarenal RAAS may be activated early in the
course of diabetes mellitus, despite normal or suppressed
levels in plasma 
21. Increased intraglomerular capillary hy-
draulic pressure, as a result of Ang II mediated efferent arte-
riolar vasoconstriction has been identified as a potential
therapeutic target for the prevention of progressive diabetic
renal damage. So, the beneficial effect of AT1R antagonism
is a result of predominant efferent arteriolar vasodilatation,
tending to lower filtration fraction and intraglomerular hy-
pertension. The result of this change is the reduction of al-
bumin urinary loss 
22. The reduction in arterial blood pres-
sure is also important, because the transmission of blood
pressure on glomerules becomes smaller. Losartan is an anti-
hypertensive drug which acts by directly blocking AT1 re-
ceptors 
23.
Genetic variations of AT1R genes can alter AT1R–me-
diated reactions by altering its expression or structure. To
date, 1166 A/C SNP has been the best evaluated of all AT1R
polymorphisms with an A to C transversion in the 3' un-
translated region of the gene. Within this SNP, the C allele
remains a candidate for genetic variations that leads to an
enhanced activity of systemic and/or paracrine RAAS 
7–9.
In patients with diabetes type 1, during hyperglycemic
clamp conditions, Miller et al 
12, demonstrated that only the
C allele carriers exibited a significantly augmented systemic
pressor response to high glucose. This observation may indi-
cate that the C allele predicts enhanced Ang II responsive-
ness. In another study with healthy subjects, the same author
demonstrated that the C allele is associated with enhanced
intrarenal and peripheral Ang II activity, resulting in an
augmented efferent arteriolar resistance 
13. The baseline val-
ues of vascular tone in AC/CC subjects were augmented with
the associated higher values of FF and intrarenal vascular re-
sistance compared to AA carriers.
Measurement of FF provides a good estimate of intra-
glomerular pressure; higher values of this parameter are as-
sociated with higher values of urinary albumin loss. Twelve
weeks of the losartan therapy in our study group decreased
FF in all participants, but the most pronaunced reduction was
observed in AC carriers. In AA homozygous subjects, a
change of FF reached bordered values of statistical signifi-
cance, while CC homozygous subjects responded by modest
dilatation of efferent arteriolas. Nevertheless, GFR remained
unchanged in all participants. Stabilization of GFR despite
the reduction of intraglomerular and systemic arterial pres-
sure is another approval of beneficial renoprotective effect of
chronic AT1R blockade.
Similar results have been demonstrated in the study
with hypertensive patients, measuring the acute renovascular
Table 2
Comparison of clinical findings among the three different genotypes
after 12 weeks treatment with losartan
AA AC CC Clinical findings
ґ  ± SD ґ  ± SD ґ  ± SD
Albuminuria (mg/24h)
 § 96 (18 – 7335) 
† 55 (16 – 783)
 ‡ 154 (17 – 1130)
GFR(mL/min/1.73m
2) 93 ± 18 92 ± 23 99 ± 20
FF 0.16 ± 0.02 0.15 ± 0.03 
† 0.18 ± 0.04
Systolic BP (mmHg) 121 ± 18
‡ 115 ± 7
‡ 120 ± 12
Diastolic BP (mmHg) 78 ± 8
‡ 75 ± 8 
‡ 85 ± 11
Reduction rate
albuminuria (%) (95% CI) 9 (1–17) 
† 11(6–17)
 ‡ 4 (-13–22)
SGF (mL/min) 3.4 ± 10.8 4.0 ± 15.4 4.7 ± 5.7
FF 0.017 ± 0.03 0.018 ± 0.024
† 0.01 ± 0.008
systolic BP (mmHg) 15.5 ± 9.4 
‡ 10.3 ± 21.5 
‡ 12.5 ± 13.2
diastolic BP (mmHg) 8.2 ± 9.2 
‡ 11.7 ± 5.6 
‡ 10.3 ± 6.2
All data are expresed as means ± SD except albuminuria. BMI – body mass index; HbA1c – hemoglobin A1c; GFR –
glomerular filtration rate; FF – filtration fraction; BP – blood pressure; CI – confidence interval; § median (minimum-
maximum); 
† p < 0.05 vs baseline;
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response to on active metabolite of losartan - EXP3174 
24. This
study confirmed the association of the C allele with higher
sensitivity to Ang II. When EXP3174 was infused, CC ho-
mozygous subjects revealed enhanced rigidity of efferent
arteriolas, compared to AA carriers, expressed by smaller re-
duction in FF with unchanged SGF. It is therefore somewhat
unexpected to find the strongest hemodynamic response in
the AC group in our study population. Neverthless, Miller et
al. 
12 observed the AC group associated with CC carriers (as
AC/CC group), while Spiering at al. 
24 pointed their exami-
nation only on homozygous subjects (AA or CC). So, the AC
genotype results in these studies remained unavailable.
In our study, losartan therapy significantly reduced
daily albuminuria in the AA genotype and AC genotype
groups. Reduction of albuminuria after a short-term treat-
ment is a hemodynamic fenomenon reflecting the highest re-
duction in FF and intraglomerular pressure at the same
genotype 
25. Redon et al. 
26 did not reveal any association of
1166 A/C AT1R polymorphism with reduction of albumin-
uria in telmisartan treated hypertensive patients. Among pa-
tients with non-diabetic renal disease Coto et al. 
6 also did
not confirm any influence of 1166 A/C polymorphism on lo-
sartan-induced reduction of proteinuria. Considering previ-
ous results, a more pronounced difference in antiproteinuric
response could be expected in AA and CC genotype. How-
ever, we found the best losartan-induced antiproteinuric re-
sponse in AC group, by the mechanisms that still could not
be easily undersood.
In our study, AA and AC carriers experienced the
greater values of systolic and diastolic blood pressure reduc-
tion, while homozygous for the C allele, expressed weaker
antihypertensive response during the study.
Good antihypertensive response in the AA carriers
group is consistent with observations of Spiering et al. 
24. In
that study of hypertensive patients it was demonstrated that
homozygous for the C allele experienced modest decrease in
blood pressure during intravenous administration of the ac-
tive metabolite of losartan. In another study, de Nus et al. 
27
also observed more pronounced mean arterial blood pressure
reduction in AA carriers comparing to the AC group after a
short-term treatment with telmisartan. In hypertensive pa-
tients with non-diabetic renal disease, treated with losartan,
singificantly decreased diastolic blood pressure in AA carri-
ers comparing to the AC group was observed 
6.
Some other studies did not confirm any association of
this gene polymorphism with antihypertensive effect of
AT1R antagonists. Kurland et al. 
17 and Redon et al. 
26 did
not find any connection between 1166 A/C AT1R polymor-
phism and individual response to irbesartan and telmisartan
therapy. Unlike the previous studies, in Russian population
of hypertensive patients, C allele carriers were more sensi-
tive to candesartan antihypertensive effect 
28. Miller et al. 
13
also found that healthy normotensive C allele carriers ex-
pressed a more pronounced reduction in blood pressure fol-
lowing the administration of single oral dose of losartan.
The reasons for these discrepancies are still not well
understood, as well as the clinical meaning of A/C AT1R
polymorphism. The 1166 AT1R allele is located in the 3' un-
coding region, so the polymorphism of this gene does not af-
fect the binding of Ang II to AT1R or signal transduction di-
rectly. So, the A/C1166 AT1R polymorphism may be linked
to another coding region of AT1R by linkage disequilibrium,
or the stability of DNA transcript of AT1R may be altered by
this polymorphism 
29. Furthermore, diabetes mellitus is asso-
ciated with local increase in the intrarenal Ang II formation,
which appears to be more dependent on paracrine factors
rather than on circulating concentrations of other RAAS
components. Because of the compensatory suppression of
systemic RAAS in diabetics, this could have completely dif-
ferent effects on blood pressure regulation, comparing to
healthy or hypertensive individuals. On the other hand, it is
not well defined if the increased sensitivity of vascular
structures to Ang II stimulation in C allele carriers arises
from differences in the number of AT1R binding sites, or
from the functional activity of this receptor 
30, 31.
Conclusion
We can conclude that examination of 1166 A/C poly-
morphism-dependent individual, systemic or paracrine re-
sponsiveness to losartan therapy must be considered as an
interreaction between systemic and intrarenal RAAS activity.
In addition, our small sample size of homozygous C allele
carriers, limits the conclusions that could be drawn from the
obtained issues of CC genotype. Neverthless, the results
from CC genotype group are almost equalized in suggestion
that these patients may be less sensitive to the AT1R antago-
nistic effects of losartan. Finally, our study provides the evi-
dence that 116A/C AT1R polymorphism could influence the
renoprotective response to treatment with losartan, making
the rational basis for future longitudinal examination of indi-
vidualized therapy with AT1R blockers.
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